The International Community of Women Living with HIV applauds the quick action of the World Health Organisation (WHO) to release guidelines on when to start ART and PrEP. The guidelines reflect an understanding of the practical needs of people living with HIV as well as key and vulnerable populations including younger women and adolescent girls at high risk of HIV acquisition.
Further, the recommendations are based on strong evidence from clinical trials. The trials indicated that early treatment yields the double benefit of improving individual health outcomes and simultaneously lowering viral loads. HIV transmission risk is lowered and the initiation of PrEP is effective in preventing HIV acquisition.
ICW is proud to have contributed to the consultation and dialogue that led to the development of these important guidelines and we will continue to monitor and provide input to WHO on the forthcoming consolidated guidelines.
Read the full statement here